![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/24/2902915/37414/en/Panbela-Therapeutics-Announces-Third-Independent-Safety-Review-of-Phase-3-ASPIRE-Clinical-Trial-DSMB-Recommended-Continuation-with-No-Trial-Modification.html
https://www.globenewswire.com/news-release/2024/06/10/2895957/37414/en/Panbela-Announces-Oral-Presentation-at-Digestive-Disease-Week-DDW.html
https://www.globenewswire.com/news-release/2024/05/15/2882900/37414/en/Panbela-Provides-Business-Update-and-Reports-Q1-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/06/2875759/37414/en/Panbela-Announces-Issuance-of-New-Patent-in-the-US-and-Canada-Patent-is-for-Claims-of-a-Fixed-Dose-Combination-of-Eflornithine-and-Sulindac.html
https://www.globenewswire.com/news-release/2024/05/01/2873655/37414/en/Panbela-to-Host-First-Quarter-2024-Earnings-Conference-Call-on-May-15-2024.html
https://www.globenewswire.com/news-release/2024/04/30/2872189/37414/en/Acceptance-of-Eflornithine-DFMO-Abstract-for-Oral-Presentation-at-Digestive-Disease-Week.html
https://www.globenewswire.com/news-release/2024/04/22/2866820/37414/en/Panbela-Therapeutics-Announces-Interim-Data-Analysis-for-ASPIRE-Trial-Pushed-to-Q1-2025.html
https://www.globenewswire.com/news-release/2024/04/18/2865349/37414/en/Panbela-Announces-Poster-Presentation-at-American-Association-for-Cancer-Research.html
https://www.globenewswire.com/news-release/2024/04/16/2864154/37414/en/Panbela-Announces-Transfer-to-OTCQB-Market.html
https://www.globenewswire.com/news-release/2024/03/26/2852750/37414/en/Panbela-Provides-Business-Update-and-Reports-Q4-and-FY-2024-Financial-Results.html